Suven Life Sciences Ltd's Q3FY25 Quarter Results
- 25 Jan 2025
Result Summary
- Suven Life Sciences Ltd reported a 51.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 62.0%.
- Its expenses for the quarter were down by 24.7% QoQ and 15.8% YoY.
- The net profit decreased 21.2% QoQ and decreased 6.3% YoY.
- The earnings per share (EPS) of Suven Life Sciences Ltd declined at 1.8 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 3.24 | 6.61 | 8.52 | -51.0% | -62.0% |
Total Expenses | 42.36 | 56.26 | 50.28 | -24.7% | -15.8% |
Profit Before Tax | -39.12 | -49.64 | -41.76 | -21.2% | -6.3% |
Tax | 0.00 | 0.00 | 0.00 | - | - |
Profit After Tax | -39.12 | -49.64 | -41.76 | -21.2% | -6.3% |
Earnings Per Share | -1.80 | -2.30 | -1.90 | -21.7% | -5.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Suven Life Sciences Ltd is a biopharmaceutical company primarily engaged in the business of discovering, developing, and commercializing novel pharmaceutical products. The company operates within the life sciences industry, focusing on central nervous system (CNS) therapies. It has been known for its research and development efforts aimed at treating neurodegenerative diseases such as Alzheimer's and Parkinson's. While specific recent developments regarding Suven Life Sciences Ltd are not available in the provided data, the company has historically been active in forming strategic partnerships and collaborations to advance its research and development goals.
Revenue
In Q3FY25, Suven Life Sciences Ltd reported a total income of ₹3.24 crores. This represents a significant decrease of 51.0% quarter-over-quarter (QoQ) from the ₹6.61 crores recorded in Q2FY25, and a 62.0% decline year-over-year (YoY) compared to ₹8.52 crores in Q3FY24. The stark reduction in total income indicates a challenging period for revenue generation in the latest quarter. The company's ability to generate income has been markedly lower than in the previous quarters, reflecting potential shifts in business performance or market conditions.
Profitability
The financial data for Q3FY25 shows that Suven Life Sciences Ltd experienced a loss before tax of ₹39.12 crores, improving from a higher loss of ₹49.64 crores in Q2FY25, marking a 21.2% reduction in losses QoQ. Compared to a loss before tax of ₹41.76 crores in Q3FY24, the loss has decreased by 6.3% YoY. The company reported no tax expenses, resulting in an identical profit after tax figure. Earnings per share stood at ₹-1.80, showing a reduction in the loss per share from ₹-2.30 in Q2FY25, and a slight improvement from ₹-1.90 in Q3FY24, corresponding to a 21.7% QoQ and a 5.3% YoY reduction in negative EPS.
Operating Metrics
The operating metrics for Suven Life Sciences Ltd in Q3FY25 indicate total expenses of ₹42.36 crores. This reflects a decrease of 24.7% from the previous quarter where expenses were ₹56.26 crores, and a 15.8% reduction compared to ₹50.28 crores in Q3FY24. The reduction in expenses suggests that the company may have implemented cost-control measures or experienced lower operational activity. The absence of tax expenses further highlights the company's current financial strategy or tax position. Overall, the financial data reflects a period of adjustments in the operational framework of Suven Life Sciences Ltd.
